Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

To get a sense of who is truly in control of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), it is important to understand the ownership structure of the business. We can see that institutions own the ...

Equities research analysts at Leerink Partnrs cut their FY2026 earnings per share (EPS) estimates for Arrowhead ...

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have been given a consensus recommendation of ...

On Monday, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on ARWR: Arrowhead Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...